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Abstract: Plasmid DNA (pDNA)-based vaccines have emerged as effective subunit vaccines 
against viral and bacterial pathogens. In this study, a DNA vaccine, namely plasmid internal 
ribosome entry site-HN/F, was applied in ovo against Newcastle disease (ND). Vaccination was 
carried out using the DNA vaccine alone or as a mixture of the pDNA and dextran-spermine 
(D-SPM), a nanoparticle used for pDNA delivery. The results showed that in ovo vaccination 
with 40 µg pDNA/egg alone induced high levels of antibody titer (P0.05) in specific pathogen-
free (SPF) chickens at 3 and 4 weeks postvaccination compared to 2 weeks postvaccination. 
Hemagglutination inhibition (HI) titer was not significantly different between groups injected 
with 40 µg pDNA + 64 µg D-SPM and 40 µg pDNA at 4 weeks postvaccination (P0.05). 
Higher antibody titer was observed in the group immunized with 40 µg pDNA/egg at 4 weeks 
postvaccination. The findings also showed that vaccination with 40 µg pDNA/egg alone was 
able to confer protection against Newcastle disease virus strain NDIBS002 in two out of seven 
SPF chickens. Although the chickens produced antibody titers 3 weeks after in ovo vaccination, 
it was not sufficient to provide complete protection to the chickens from lethal viral challenge. 
In addition, vaccination with pDNA/D-SPM complex did not induce high antibody titer when 
compared with naked pDNA. Therefore, it was concluded that DNA vaccination with plasmid 
internal ribosome entry site-HN/F can be suitable for in ovo application against ND, whereas 
D-SPM is not recommended for in ovo gene delivery.
Keywords: Newcastle disease, DNA vaccine, in ovo vaccination, Newcastle disease virus, 
dextran-spermine nanoparticle, hemagglutinin and fusion
Introduction
The administration of DNA vaccines is an advanced approach to achieve specific immune 
system activation.1,2 The advantages of DNA vaccines such as the capacity to be delivered 
in ovo, the potential to overcome maternal immunity, non-requirement for cold chain 
transport, and the ability to mix with immunological factors to reach high efficiency have 
made them more attractive for use in the poultry industry. It has been demonstrated that 
recombinant DNA transfection into avian embryos is a problematic approach.2 Hence, in 
adult animals, DNA vaccines are most commonly delivered via intradermal or intramus-
cular injections; a few studies have focused on embryonic administration.3–5 Administra-
tion of plasmid DNA (pDNA) containing the reporter beta galactosidase gene into the 
avian embryo body produced the protein, although it can increase the mortality rate.3 
Avian embryo is competent  immunologically after the 17th day of embryonic stages.6–8 
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Therefore, it was hypothesized that a DNA vaccine could be 
administered into the amniotic sac of avian embryos to induce 
immunity at this stage.
Few factors such as cell membrane, in vivo stability, 
endosome escape, nuclear entry, and cytosolic transport act 
as barriers that inhibit the delivery of DNA into the host cells. 
DNA vaccines can be efficiently delivered using cationic 
lipids and/or cationic polymers. A study showed that DNA 
when covered by these particles resulted in a complex with 
positive charge that enhanced the endocytosis process through 
which the DNA entered the cell. Cationic polymers created 
more stable complexes than cationic lipids; thus, they provide 
more protection to the vaccines through cellular trafficking.7–10 
Cationic polysaccharides are biodegradable and nontoxic and 
can be easily modified to exhibit different physicochemical 
properties.11 Usage of biodegradable polysaccharide car-
riers are especially appropriate for biological applications 
such as transaction, because they are soluble in water and 
freely transported to the cells.12 Polysaccharide dextran is 
a complex, diverged glucan with a chain length from 3 to 
2,000 kDa and is prepared by using many glucose molecules. 
Recently, dextran-spermine (D-SPM) has been developed as 
a novel cationic polymer for gene delivery. A recent study 
has suggested a new biodegradable polycation made up of 
natural components, which is efficient in transfecting tissues 
and cells in vitro and in vivo.13 This polycation has shown 
an effective transfection for a range of cell lines and genes 
in serum-poor or serum-free medium.14 D-SPM polycations 
have been found to be active in transfecting a wide range of 
cell lines in vitro.15 Therefore, the objectives of the present 
study were: 1) to determine that a DNA plasmid coexpressing 
the fusion (F) and hemagglutinin (HN) proteins of Newcastle 
disease virus (NDV) can be a potential vehicle for success-
ful vaccination in ovo against ND; and 2) to test whether the 
cationic polysaccharide D-SPM can be used to enhance the 
efficacy of in ovo delivery of the DNA vaccine against ND.
Materials and methods
construction of DNa vaccine
The plasmid internal ribosome entry site (pIRES) coexpres-
sion vector containing multiple cloning sites (MCS) such as 
MCS A and MCS B with a size of 6.1 kb (Clontech, Palo Alto, 
CA, USA) was used to construct a DNA plasmid encoding 
the F and HN genes of NDV AF2240 strain. The full lengths 
of the F and HN genes were amplified using reverse tran-
scription polymerase chain reaction (RT-PCR) using a pair 
of F-specific primers and HN-specific primers with sequence 
for the restriction enzymes NheI and MluI, and SalI and NotI, 
respectively, introduced into the forward and reversed prim-
ers regard to conserving frameshift of sequences:
F-For: 5′AATTCGGCTAGCACCATGGGCTCCAAG
TCTT3′
F-Rev: 5′GGCACGCGTCTAGCTGCCAGAATTGA
CGCGCA3′
HN-For: 5′CAGTCGACGTCATGGGGAACCAGGC
CTCACAA3′
HN-Rev: 5′GAGCGGCCGCCCTATTGACAAGAAT
TCAGGCCAT3′.
The RT-PCR products of F and HN genes with a length of 
1,722 and 1,950 base pairs (bp), respectively, were amplified 
and cloned into the NheI and MluI (inserted into MCS A) and 
SalI and NotI (inserted into MCS B) of the pIRES vector to the 
construct pIRES-HN/F DNA plasmid. The construct was puri-
fied using an endotoxin-free plasmid purification kit (Qiagen 
NV, Venlo, the Netherlands) following verification of the orien-
tation and nucleotide sequence of the inserts by double-stranded 
sequencing. Expression of both HN and F genes together in 
a pIRES-HN/F plasmid was confirmed using both indirect 
immunofluorescence and Western blotting techniques.
Preparation of pDNa/D-sPM complex
D-SPM was prepared as previously described by Abedini 
et al.16 pDNA/D-SPM nanoparticles were prepared by mixing 
pDNA and D-SPM at various concentrations in aqueous 
solution. A volume of 100 µL of DNase-free water was taken 
in five separate tubes containing 8, 12, 16, 18, and 20 µg of 
D-SPM and placed in a sonicator (Branson, Danbury, CT, 
USA) for 30 minutes. To each test tube, 10 µg of pDNA was 
added and the solutions were pipetted up and down three to 
five times and then placed in an orbital mixer for 10 minutes 
at room temperature. The solutions of pDNA and D-SPM 
were mixed and gently agitated for 30 minutes to form self-
assembled pDNA/D-SPM complexes.
characterization of the self-assembled 
pDNa
The reliability of covering pDNA by D-SPM was tested 
on 1% agarose gel. The formation of DNA complexes was 
also confirmed by transmission electron microscopy (TEM). 
Fifty microliters of the sample was kept on a copper grid for 
5 minutes; excess solution was blotted off using filter paper 
and air-dried for 5 minutes before viewing by TEM.
Particle size assayed by NaNOPhOX
Fresh pDNA/D-SPM complex was prepared with a fixed 
concentration of pDNA and a varying concentration of 
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D-SPM and then the mean particle size was analyzed by a 
particle size analyzer (NANOPHOX, Sympatec, Germany). 
The size of all the dispersed samples in nuclease-free water 
was determined at 25°C in triplicate. Photon cross correlation 
sensor present in this analyzer allowed for the simultaneous 
determination of particle size and stability in a range, approxi-
mately, of 1 nm to several micrometers in opaque suspensions 
and emulsions.17
Zeta potential and size measurement
Zeta potential is commonly used to characterize the surface 
charge property of nanoparticles.18 Size and zeta potential 
of nanoparticles were determined using a laser particle size 
analyzer (Malvern, Zeta, Worcestershire, UK). A tenfold 
dilution of the sample in pure water in a total volume of 1 mL 
was subjected to a particle size analyzer at 25°C. The mea-
surement was based on the electrophoretic mobility (µm/s) of 
the particles which was converted to zeta potential by inbuilt 
software based on the Helmholtz–Smoluchowski equation.
In ovo vaccination of sPF embryo
Eighteen-day-old embryonated specific pathogen-free (SPF) 
eggs were randomly divided into four groups (15 eggs per 
group). The eggs were inoculated with 40 µg pIRES-HN/F, 
20 µg pIRES-HN/F +32 µg D-SPM, and 40 µg pIRES-
HN/F + D-SPM complex or the empty plasmid. The egg 
shells were disinfected and the vaccines were injected via 
the aminio-allantoic cavity through a small hole made at the 
air sacs with 21-gauge needle followed by sealing the holes 
and continued the incubation of the eggs. After hatching, the 
chicks had free access to feed and water. Bleeding was car-
ried out at 2, 3, and 4 weeks post-immunization; total serum 
antibody titers were measured by an indirect enzyme-linked 
immunosorbent assay (ELISA) Kit (IDEXX, Westbrook, ME, 
USA) and hemagglutination inhibition (HI) test as previously 
described.19 The chickens were treated and handled according 
to the protocols approved by the Institutional Animal Care 
and Use Committee (IACUC) of the Faculty of Veterinary 
Medicine (AUP no. 12R1541), Universiti Putra Malaysia.
Virus challenge
After 4 weeks of in ovo vaccination, the vaccinated chickens 
in all groups were challenged with intranasal administration 
of 105 mean egg infection dose (EID
50
) of either NDV strain 
AF2240 or NDV strain IBS002 in a volume of 0.1 mL viral 
suspensions per chick. The chickens were monitored daily 
after challenge for 10 days and the numbers of dead chickens 
were recorded.
statistical analysis
Data were analyzed by Student’s t-test and statistical sig-
nificance was set at P0.05. The results were expressed as 
mean ± standard error of the mean. All the analyses were 
carried out using Minitab 15 Statistical Software (Minitab 
Inc., University Park, PA, USA) and Microsoft Excel 2010 
(Microsoft Corporation, Redmond, WA, USA). 
Results
agarose gel electrophoresis of pDNa/ 
D-sPM complex at different ratios
The DNA vaccine pIRES-HN/F was constructed to express 
HN and F genes of NDV strain AF2240. The pDNA/D-SPM 
nanoparticles were prepared by mixing pIRES-HN/F and 
D-SPM at various concentrations. The formation of nanopar-
ticles was tested by performing electrophoresis of the samples 
on 1% agarose gel, where the absence of DNA band on the gel 
indicates the initial formation of a stable complex (Figure 1).
Particle size analysis
The formation of nanoparticles and particle sizes of the 
pDNA/D-SPM complexes were also checked by TEM. 
Good agglomeration and a particle size of ~70–130 nm 
were obtained when a mixture of 10 µg of pDNA and 16 µg 
of D-SPM was used to prepare the nanoparticles (Figure 2). 
In addition, the particle size of the pDNA/dextran complexes 
was determined by nanophox equipment (NANOPHOX). 
As shown in Figure 3, a particle size of 10–100 nm was 
obtained when a mixture of 10 µg of pDNA and 16 µg of 
D-SPM was used.
    
Figure 1 agarose gel electrophoresis of the pDNa/D-sPM complex at different 
ratios.
Notes: line 1, free pDNa plasmid; lines 2–4, pDNa/D-sPM complexes at ratios 12, 16, 
and 18 µg, respectively; line 5, generuler generulerTM DNa ladder 1 kb (Fermentas 
canada, Burlington, ON, canada).
Abbreviations: pDNa, plasmid DNa; D-sPM, dextran-spermine.
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size distribution of pDNa with D-sPM 
nanoparticle complexes
In addition, the size distribution of the pDNA/D-SPM 
complexes were determined with a Zetasizer 3000 HSA 
(Malvern); when a mixture of 10 µg of pDNA and 16 µg of 
D-SPM nanoparticles was used, DNA nanoparticles of 75 nm 
size were obtained, as shown in Figure 4A.
Zeta potential report of pDNa with 
D-sPM nanoparticle complexes
A zeta potential in the range of 25–30 mV was used for the 
preparation of pDNA/D-SPM complexes in a ratio of 10 µg 
pDNA to 16 µg of D-SPM (Figure 4B).
As expected, the zeta potential of pDNA alone was 
found to be in a range of −55 to −60 mV (Figure 5A). The 
backbone of DNA is highly charged and each bp carries two 
unit negative charges and each phosphate group carries one 
unit negative charge. The surface charge of nanoparticles 
with a zeta potential around ±30 mV has been revealed 
to be stable in suspension, and this surface charge stops 
aggregation of the particles. For D-SPM alone, the sur-
face charge was determined to be in a range of 30–35 mV 
(Figure 5B).
In ovo immunization of sPF chickens
In ovo immunization was carried out using naked DNA 
plasmid and pDNA + D-SPM complexes. After hatching, 
an immune response was assessed at 2, 3, and 4 weeks 
postvaccination.
NDV antibody response by elIsa
The antibody titer was evaluated at a serum dilution of 1:500 
using commercial ELISA kit (IDEXX). The positive control 
mean was 0.165 and the negative control mean was 0.046.
ELISA results were presented as an S/P ratio. An S/P ratio 
is determined by dividing the absorbance units (ELISA score) 
of the sample in question by the ELISA score of a positive 
control analyzed alongside the test sample(s). An S/P ratio is 
directly correlated with the amount of target antigen present 
in the sample.
As shown in Table 1 and Figure 6, no anti-NDV immune 
response was detected in the controls vaccinated with the 
empty plasmid. Antibody levels remained low 2 weeks after 
QPQP
QP
QP
Figure 2 Particle size analysis of pDNa/D-sPM complexes by transmission electron 
microscopy (TeM).
Notes: Nanoparticle sizes between 74 and 127 nm were obtained from the pDNa/
dextran complexes. scale bar =1,000 nm. These arrows point to the size of pDNa/
D-sPM complexes.
Abbreviations: pDNa, plasmid DNa; D-sPM, dextran-spermine.
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Figure 3 NaNOPhOX particle size analysis of the pDNa/D-sPM complexes.
Abbreviations: pDNa, plasmid DNa; D-sPM, dextran-spermine; VMD, volume mean diameter.
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in ovo immunization in all the vaccinated groups. A higher 
antibody titer was observed in the group immunized with 
40 µg pDNA at 4 weeks postvaccination; however, it was 
not significant compared to the chickens immunized with 
40 µg pDNA +64 µg dextran complex (P0.05). The lowest 
antibody titer was obtained in groups vaccinated with 20 µg 
pDNA +32 µg dextran complex compared to other vaccinated 
groups (P0.05).
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Figure 4 Zeta potential of pDNa and D-sPM.
Notes: (A) size distribution of pDNa with D-sPM nanoparticle complexes by Zetasizer 3000 hsa. Plasmid DNa and D-sPM nanoparticles when used in a ratio of 10:16 
produced a complex of size 75 nm. (B) Zeta potential report of pDNa/D-sPM complexes. The range of zeta potential of the pDNa/D-sPM complexes at a ratio of 10 of µg 
plasmid DNa to 14 µg or 16 µg of D-sPM was 25–30 mV.
Abbreviations: pDNa, plasmid DNa; D-sPM, dextran-spermine.
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Figure 5 Zeta potential of pDNa and D-sPM.
Notes: (A) Zeta potential report of pDNa alone. The zeta potential of backbone plasmid DNa ranged from −55 to −60 mV. (B) Zeta potential report of D-sPM alone. The 
surface charge of D-sPM alone was determined to be in a range of 30–35 mV.
Abbreviations: pDNa, plasmid DNa; D-sPM, dextran-spermine.
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NDV-hN antibody titers by hI test
The HI test was carried out on serum samples with four 
hemagglutination (HA) units of the mucosal LaSota vaccine. 
A twofold dilution of each serum was made and titers were 
expressed as log 2 values of the highest dilution of serum 
inhibiting hemagglutination. The mean HI titers are shown in 
Table 2. HI titer was not significantly different between the 
groups injected with 40 µg pDNA +64 µg D-SPM (3.5±0.51) 
and 40 µg pDNA (3.43±0.22). However, the mean HI titer 
was significantly lower in the groups vaccinated with 20 µg 
pDNA +32 µg D-SPM (2.73±0.04) compared to the other 
vaccinated groups.
Virus challenge
Four weeks post-immunization, chickens were challenged with 
NDV AF2240 and IBS002 strains. In the AF2240-challenged 
chickens, regular death was first detected 3 days post-challenge 
and the last death was recorded on the fifth day for all the 
control chickens. Clinical signs such as the wing or leg 
paralysis and weakness were observed on the third day post-
challenge and the chickens began to die. After 1 week post-
challenge, all the chickens in all the vaccinated groups died 
(Table 3). However, chickens immunized with pIRES-HN/F 
(40 µg pDNA/egg) and challenged with IBS002 were more 
active and showed no signs of disease even after 3 days post-
challenge and finally two chickens survived. Furthermore, 
one chicken in each pIRES-HN/F group vaccinated with 
40 µg pDNA + D-SPM/egg or 20 µg pDNA + D-SPM/egg 
died 8 days post-challenge (Table 4).
In all the challenged chickens, depression and loss of 
appetite were observed. Severe manifestations such as 
edema, hemorrhages, and necrosis of respiratory tissue 
were found in dead chickens of the control group, whereas 
no significant gross lesions were found in the vaccinated 
group.
However, pIRES-HN/F-immunized chickens showed no 
signs of the disease even after 3 days of the challenge and 
finally two chickens survived (Table 4).
Table 1 analysis of s/P ratios of elIsa results
Group S/P ratio of ELISA results
2 weeks 3 weeks 4 weeks
pIres-hN/F (40 µg pDNa) 0.038±0.00 0.248±0.02 0.272±0.02
pIres-hN/F (40 µg pDNa + D-sPM) 0.035±0.00 0.209±0.01 0.251±0.02
pIres-hN/F (20 µg pDNa + D-sPM)
pIres
0.022±0.04
0.00
0.063±0.00
0.00
0.085±0.02
0.00
Note: s/P ratio = sample mean (mean of optical absorbance) – negative control mean/positive control mean – negative control mean.
Abbreviations: elIsa, enzyme-linked immunosorbent assay; pIres, plasmid internal ribosome entry site; hN, hemagglutinin; F, fusion; pDNa, plasmid DNa; D-sPM, 
dextran-spermine.
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Figure 6 Mean s/P ratio of elIsa result after in ovo immunization with pIres-hN/F or pIres-hN/F-D-sPM complexes.
Notes: The error bars show standard deviation of means. s/P ratio = sample mean (mean of optical absorbance) – negative control mean/positive control mean – negative 
control mean.
Abbreviations: elIsa, enzyme-linked immunosorbent assay; pIres, plasmid internal ribosome entry site; hN, hemagglutinin; F, fusion; D-sPM, dextran-spermine; Nano, 
nanoparticle.
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Table 2 Mean antibody titers determined by hI test (log2) of sPF embryonated eggs after immunization with different vaccination 
programs (geometric mean ± sD)
Group Mean HI titer in different weeks of postvaccination (log2)
2 weeks 3 weeks 4 weeks
pIres-hN/F (40 µg pDNa) 1.93±0.47 2.14±0.53 3.43±0.22
pIres-hN/F (40 µg pDNa + D-sPM) 1.36±0.49 1.71±0.61 3.5±0.51
pIres-hN/F (20 µg pDNa + D-sPM) 1.64±0.50 1.64±0.5 2.73±0.04
pIres 1.1±0.31 1.1±0.31 1.1±0.31
Abbreviations: HI, hemagglutination inhibition; SPF, specific pathogen-free; pIRES, plasmid internal ribosome entry site; HN, hemagglutinin; F, fusion; pDNA, plasmid DNA; 
D-sPM, dextran-spermine.
Table 3 results of virus challenge with the NDV aF2240 strain after in ovo vaccination
Vaccinated groups Sample numbers 2 days 3 days 4 days 5 days 6 days Survived
pIres-hN/F (40 µg pDNa) 7 0 2 3 2 0 0
pIres-hN/F (40 µg pDNa + D-sPM) 7 0 2 3 1 1 0
pIres-hN/F (20 µg pDNa + D-sPM) 6 0 2 3 1 0 0
pIres 10 0 3 5 2 0 0
Note: sample numbers are the numbers of hatched chicks after in ovo vaccination.
Abbreviations: NDV, Newcastle disease virus; pIres, plasmid internal ribosome entry site; hN, hemagglutinin; F, fusion; pDNa, plasmid DNa; D-sPM, dextran-spermine.
Discussion
It is thought that F and HN glycoproteins interact with one 
another to promote F activity and, therefore, immunization 
with a DNA plasmid encoding both F and HN genes would 
be more effective than either component alone.20–22 Therefore, 
in this research, the DNA plasmid pIRES-HN/F coexpress-
ing F and HN proteins was constructed and used for in ovo 
immunization against NDV. Immunization with 40 µg of 
pIRES-HN/F per egg induced a significant level of antibody 
titer; however, it was not effective in protecting against the 
virus challenge. This deficiency may be correlated to the 
relatively low transfection efficiency of the pDNA into the 
cells. Enzymes and serum proteins such as endonucleases 
may degrade the plasmid, and thereby reduce the available 
plasmids in the host cells that express the antigen.
In the present study, 1×105 EID
50
 of the virulent NDV 
was used by the nasal route for challenge trials.
This dose was considered to be high to test the efficacy 
of the DNA vaccines. Therefore, the trial infection can be 
applied on statistically significant number (10) of adult 
and young chickens (contact challenge) with a viral standard 
dose as 105 EID
50
.23 Thus, virus challenges via contact route 
rather than nasal route may provide more protection against 
virulent viruses.
For most DNA vaccines, direct inoculation has been 
shown not to be effective enough due to electrostatic repul-
sion between the negatively charged DNA and positively 
charged cell membrane. Enzymatic degradation is another 
negative point that subsequently inhibits effective cellular 
uptake. DNA hydrolyzing activity by DNase I is also 
observed in blood plasma. Hence, the amount of foreign 
DNA that crosses the cytoplasm varies and depends on the 
DNase I activity.24
Therefore, to deliver DNA molecules into cells, a studies 
have used D-SPM, which is a polycationic polysaccharide.25,26 
D-SPM can bind to DNA through a combination of electro-
static attraction and intercalation. In this study, D-SPM 
was used as a nanoparticle for in ovo delivery of a DNA 
vaccine. The results showed that pDNA/D-SPM complex 
can induce antibody titer in a low level compared to pDNA 
alone. The results of in ovo immunization are summarized 
in Table 4; the table shows (P0.05) low S/P ratio obtained 
by ELISA at 4 weeks post-immunization of groups injected 
with pDNA + D-SPM compared to groups injected with 
pDNA alone, suggesting that D-SPM may not be effective 
in delivering pDNA to the cell by an in ovo method, thus 
resulting in low pDNA transfection efficiency.
This deficiency in vaccine efficacy may be due to the num-
ber of positive charges and the charge spacing of polyamine 
molecules in pDNA/D-SPM complex within the amniotic 
liquid that surrounds the chicken embryo. Studies on λ-DNA 
concentration by spermine homologues showed that the mid-
point concentration of polyamine homologues for contracting 
DNA and the hydrodynamic ranges of the condensates are 
dependent on the polyamine structure.26 On the other hand, 
the most abundant protein in white egg is ovalbumin, repre-
senting 54% of the total protein content.27 It has been shown 
that at pH levels between 9.6 and 6.6, there is transference 
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Table 4 Number of dead chickens at days post-challenge with IBs002 strain
Vaccinated groups Sample numbers 2 days 3 days 4 days 5 days 6 days 8 days Survived
pIres-hN/F (40 µg pDNa) 7 0 0 2 2 1 0 2
pIres-hN/F (40 µg pDNa + D-sPM) 7 0 0 2 3 1 1 0
pIres-hN/F (20 µg pDNa + D-sPM) 6 0 0 2 1 1 1 0
pIres 10 0 0 4 4 2 – 0
Note: sample numbers are the numbers of hatched chicks after in ovo vaccination.
Abbreviations: pIres, plasmid internal ribosome entry site; hN, hemagglutinin; F, fusion; pDNa, plasmid DNa; D-sPM, dextran-spermine.
of albumin to dextran when the two components are mixed, 
the amount of albumin lost being nearly equal to the gain in 
the new component, albumin plus dextran.28 Polysaccharide 
such as dextran shows high viscosity, which helps in the 
stabilization of emulsion with ovalbumin.29
Therefore, in the present study, low antibody titer induced 
in the chickens immunized with the pDNA nanoparticle can 
be related to the low efficacy of D-SPM in delivering pDNA to 
the embryo cell. According to the manufaturer’s instrcutions, 
S/P values lower than 0.5 are considered negative. Thus, in 
ovo vaccination resulted in a slight increase in antibody titers, 
which are too low to be considered as seroconversion.
The basis of immunity against NDV is circulating 
antibodies and cell-mediated immunity. In this study, the 
stimulation of B cells (antibodies) by the constructed plasmid 
was not strong enough to elicit T cell–independent induction 
of IgM antibodies. In summary, protection against lethal 
challenge could not be expected when DNA vaccines were 
delivered in ovo.
Conclusion
This study revealed that although in ovo vaccination did not con-
fer significant protection from the subsequent NDV challenge, 
a significant increase in the production of antibodies in the 
chicks vaccinated with pIRES-HN/F was achieved. This is the 
first study to report on the testing of D-SPM for the delivery of 
pDNA in ovo. This study described a set of experiments inves-
tigating a new DNA vaccine containing NDV F and HN genes 
and D-SPM to support DNA delivery for in ovo vaccination to 
protect chickens against the lethal Newcastle disease. Further 
investigation using a different virus titer and contact route for 
challenge to test the efficacy of different immunizations will 
help improve the nanoparticle DNA vaccine.  Biotechnological 
studies today have mainly focused on safe and efficient nano-
delivery of pDNA into chicken embryo cells.
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